-
-
-
-
-
-
-
Mirum Pharmaceuticals Announces New PDUFA Date for LIVMARLI for the Treatment of Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis
-
-
-
-
-
-
-
Mirum Pharma (MIRM) Submits European MAA for Maralixibat in Alagille Syndrome Supported by New Positive Results from Natural History Study Comparison
-
-
-
-
-
-
-
Mirum Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Mirum Pharmaceuticals to Showcase Analyses From Its Rare Liver Disease Programs at The International Liver Congress 2021
-
-
-
-
-
-
-
Mirum Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
-
-
-
12,447 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All